BRPI0514976A - composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto - Google Patents

composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto

Info

Publication number
BRPI0514976A
BRPI0514976A BRPI0514976-2A BRPI0514976A BRPI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A BR PI0514976 A BRPI0514976 A BR PI0514976A
Authority
BR
Brazil
Prior art keywords
compound
alkyl
substituted
pharmaceutical composition
15beta
Prior art date
Application number
BRPI0514976-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Hubert Jan Jozef Loozen
Antonius Gerardus Hen Ederveen
Fredericus Antonius Dijcks
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of BRPI0514976A publication Critical patent/BRPI0514976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0514976-2A 2004-09-08 2005-09-05 composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto BRPI0514976A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60850104P 2004-09-08 2004-09-08
EP04104334 2004-09-08
PCT/EP2005/054368 WO2006027347A1 (en) 2004-09-08 2005-09-05 15β-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY

Publications (1)

Publication Number Publication Date
BRPI0514976A true BRPI0514976A (pt) 2008-07-01

Family

ID=34929554

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514976-2A BRPI0514976A (pt) 2004-09-08 2005-09-05 composto esteroidal 15beta-substituìdo, composição farmacêutica, e, uso de um composto

Country Status (20)

Country Link
US (1) US7838516B2 (enExample)
EP (1) EP1805201B1 (enExample)
JP (1) JP4889644B2 (enExample)
AR (1) AR050732A1 (enExample)
AT (1) ATE414710T1 (enExample)
AU (1) AU2005281705B2 (enExample)
BR (1) BRPI0514976A (enExample)
CA (1) CA2577497C (enExample)
DK (1) DK1805201T3 (enExample)
ES (1) ES2317312T3 (enExample)
NZ (1) NZ553266A (enExample)
PE (1) PE20060590A1 (enExample)
PL (1) PL1805201T3 (enExample)
PT (1) PT1805201E (enExample)
RS (1) RS51640B (enExample)
RU (1) RU2386637C2 (enExample)
SI (1) SI1805201T1 (enExample)
TW (1) TW200621795A (enExample)
UA (1) UA89964C2 (enExample)
WO (1) WO2006027347A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
EP2448910B1 (en) * 2009-06-29 2013-05-15 Merz Pharma GmbH & Co. KGaA Method of preparing neramexane
BRPI1012669A2 (pt) * 2009-06-29 2016-04-05 Merz Pharma Gmbh & Co Kgaa metodo de preparacao de 3,3,5,5-tetrametliciclohexanona, método de preparção de 1-amino-1,3,3,5,5,-pentametilciclohexano ou um sal farmaceuticamente aceitável do mesmo e composto
CA2765609A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2764008B1 (en) * 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
MX2015017879A (es) 2013-06-25 2017-03-01 Forendo Pharma Ltd Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
CN105518017B (zh) 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
CN107207562B (zh) 2014-12-23 2020-03-06 佛恩多制药有限公司 17β-HSD1抑制剂的前药
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
RS57328B1 (sr) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (en) 2015-06-18 2016-12-22 Mithra Pharmaceuticals S.A. Orodispersible tablet containing estetrol
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
NZ737945A (en) 2015-06-18 2023-06-30 Estetra Sprl Orodispersible dosage unit containing an estetrol component
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
WO2018224736A2 (en) 2017-06-08 2018-12-13 Forendo Pharma Ltd Therapeutically active steroidal derivatives
CR20200486A (es) 2018-04-19 2021-01-27 Estetra Sprl Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
MX2021006452A (es) 2018-12-05 2021-09-28 Forendo Pharma Ltd Compuestos estra-1,3,5(10)-trieno condensados en posición 16(17) con un anillo de pirazol como inhibidores de 17-hsd1.
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL226738A (enExample) 1957-04-11
DE1084261B (de) 1957-04-11 1960-06-30 Syntex Sa Verfahren zur Herstellung neuer Cyclopentanophenanthrenderivate
US3257429A (en) * 1957-11-12 1966-06-21 Syntex Corp 16-methylene derivatives of estrone and estradiol
US3007946A (en) 1958-11-06 1961-11-07 Searle & Co 3-alkoxy-16-methylene-1, 3, 5(10)-estratrien-17-ones
US3049555A (en) 1959-12-22 1962-08-14 Searle & Co 3-alkoxy-16-methyl-1, 3, 5 (10)-estratrien-17-ones
US3092645A (en) 1961-12-28 1963-06-04 Searle & Co Esters of 17alpha-alkynylester-5(10)-ene-3beta, 17beta-diols
GB1112840A (en) 1964-04-07 1968-05-08 Res Inst Medicine Chem Steroids having pro-oestrogenic activity
US3299108A (en) 1965-10-18 1967-01-17 Searle & Co 17alpha-alkynyl/alkenyl-13beta-alkyl-11-alkylgona-1, 3, 5 (10)-triene-3, 17beta-diols, ethers and esters thereof and intermediates thereto
US3465010A (en) 1966-11-22 1969-09-02 Searle & Co 17 - (unsaturated hydrocarbon - substituted) 11,13beta - dialkylgon -4 - ene - 3,17beta-diols and esters thereof
US3377366A (en) 1966-12-02 1968-04-09 Searle & Co 17alpha-alkynyl/alkenyl-11, 13beta-dialkylgon-5(10)-en-3-ones and esters thereof
US3642992A (en) * 1967-09-08 1972-02-15 Upjohn Co Organic compounds
ZA712312B (en) 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds
US3652606A (en) 1970-08-07 1972-03-28 Searle & Co 3-oxygenated 11beta-methylestr-4-en-17beta-ol and esters thereof
US3704253A (en) 1970-09-23 1972-11-28 American Home Prod 13 - polycarbonalkyl - 16 - methylgona-1,3,5(10)-trienes and 13-polycarbonalkyl-16-methylgon - 4 - en-3-ones and intermediates for their production
US3766224A (en) * 1971-06-03 1973-10-16 Sandoz Ag 15-methyl-substituted steroids
FR2377419A1 (fr) 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 11b-substitues 1,3,5 (10) trieniques, leur procede de preparation et leur application comme medicament
DE2757157C3 (de) 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
AU572589B2 (en) 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
US5116830A (en) 1984-08-17 1992-05-26 Sri International Stereoisomerically pure 17α-ethynyl-estra-2-en-17β-ol and the 17β esters thereof, methods of preparation and uses
US5204337A (en) 1988-10-31 1993-04-20 Endorecherche Inc. Estrogen nucleus derivatives for use in inhibition of sex steroid activity
ZA94715B (en) 1993-02-08 1994-10-24 Akzo Nv Steroids for treating menopausal complaints
ZA941464B (en) 1993-03-05 1994-09-27 Akzo Nv Use of pregnane derivative
CA2200423C (en) 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
IL123195A (en) 1997-02-21 2002-11-10 Akzo Nobel Nv Steroid compounds with anti-pregnancy activity and against bone thinning, preparation and pharmaceutical preparations containing them
JP2002506014A (ja) 1998-03-09 2002-02-26 アクゾ・ノベル・エヌ・ベー 新規な避妊用キット
RU2216546C2 (ru) 1998-06-19 2003-11-20 Акцо Нобель Н.В. СОЕДИНЕНИЕ (7α,17β)-7-МЕТИЛ-17-[(1-ОКСОУНДЕЦИЛ)ОКСИ]ЭСТР-4-ЕН-3-ОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, НАБОР ДЛЯ МУЖСКОЙ КОНТРАЦЕПЦИИ
WO2000031112A1 (en) 1998-11-20 2000-06-02 Akzo Nobel N.V. Estrogenic estra-1,3,5(10)-trienes with differential effects on the alpha and beta estrogen receptors, having a linear hydrocarbon chain of from 5-9 carbon atoms in position 11
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
SK3282002A3 (en) 1999-09-06 2002-06-04 Akzo Nobel Nv Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
HRP20030060A2 (en) * 2000-07-28 2004-06-30 Akzo Nobel Nv 16alpha-methyl or ethyl substituted estrogens

Also Published As

Publication number Publication date
JP2008512426A (ja) 2008-04-24
PL1805201T3 (pl) 2009-04-30
CA2577497A1 (en) 2006-03-16
AU2005281705A1 (en) 2006-03-16
US7838516B2 (en) 2010-11-23
AR050732A1 (es) 2006-11-15
ES2317312T3 (es) 2009-04-16
NZ553266A (en) 2009-06-26
RS20070075A (sr) 2008-09-29
RU2386637C2 (ru) 2010-04-20
DK1805201T3 (da) 2009-01-12
SI1805201T1 (sl) 2009-04-30
EP1805201A1 (en) 2007-07-11
ATE414710T1 (de) 2008-12-15
CA2577497C (en) 2012-03-20
EP1805201B1 (en) 2008-11-19
JP4889644B2 (ja) 2012-03-07
WO2006027347A1 (en) 2006-03-16
RU2007112939A (ru) 2008-11-10
PT1805201E (pt) 2008-12-31
PE20060590A1 (es) 2006-07-14
RS51640B (sr) 2011-10-31
US20070254860A1 (en) 2007-11-01
AU2005281705B2 (en) 2011-03-10
TW200621795A (en) 2006-07-01
UA89964C2 (ru) 2010-03-25

Similar Documents

Publication Publication Date Title
BR0009320A (pt) Dibenzopiranos como antagonistas do receptor glicocorticóide para o tratamento da diabete
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BRPI0512985A (pt) derivados de 3-carbamoil-2-piridona
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0513184A (pt) derivados de 2-carbamida-4-feniltiazol, preparação dos mesmos e aplicação dos mesmos em terapia
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
BRPI0520812A2 (pt) método para preparar um composto de quinolina 4-substituìda, e, composto
BR0214023A (pt) Derivados de 1,2,4-tiadiazólio como moduladores de receptor de melanocortina
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BR0308945A (pt) Derivados radiomarcados de quinolina e quinolinona e uso dos mesmos como ligantes para receptores de glutamato metabotrópicos
BRPI0607523A2 (pt) compostos esteróides de heteroarila c-17, composições farmacêuticas compreendendo os mesmos e uso dos referidos compostos na preparação de medicamentos
DE69926919D1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR0312069A (pt) Compostos de benzimidazol e seu uso como agonistas/antagonistas de estrogênio
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
BR0012697A (pt) Inibidores da diferenciação de th2
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
UA89964C2 (ru) 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
CL2007002329A1 (es) Compuestos derivados de 5,6-bisaril-2-piridin carboxamida, inhibidores de urotensina ii; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir insuficiencia cardiaca congestiva, is
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BR0311410A (pt) Composto de piperidina
BRPI0912171A8 (pt) Composto ativador de receptor de glicocorticoide, e, composição
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2227 DE 10/09/2013.